Early data from the Phase III TALAPRO-2 study showed Talzenna (talazoparib), Pfizer’s oral PARP inhibitor, met its primary endpoint in metastatic castration-resistant prostate cancer patients, the company announced Tuesday.
https://www.pharmalive.com/wp-content/uploads/2021/12/Pfizer-Halts-DMD-Gene-Therapy-Trial-to-Uncover-Cause-of-Patient-Death-BioSpace-12-21-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-10-04 11:05:062022-10-04 11:05:06Pfizer, Clovis make inroads against tough to treat prostate cancer
